Elafibranor is a medication being studied for treating Primary Biliary Cholangitis (PBC), a liver condition. It works by targeting certain receptors in the liver that help reduce inflammation and improve liver function. This medication is taken orally and is being tested in patients who haven’t responded well to standard treatments or couldn’t tolerate them.

Ursodeoxycholic Acid is a standard medication used to treat Primary Biliary Cholangitis. It’s a naturally occurring bile acid that helps improve liver function by reducing the buildup of harmful bile acids. This medication is mentioned as the previous treatment that patients in the study either didn’t respond well to or couldn’t tolerate.

Primary Biliary Cholangitis (PBC) – A chronic liver disease that primarily affects women and slowly damages the bile ducts in the liver. The condition causes inflammation and scarring of the small bile ducts, which leads to bile buildup in the liver. Over time, this progressive disease causes the bile ducts to be destroyed, allowing harmful substances to build up in the liver. The disease typically develops slowly over many years, gradually affecting the liver’s ability to function properly. PBC often begins with inflammation that may cause fatigue and itching, while the bile ducts become increasingly damaged.